How obesity damages the skeletal muscle metabolism
A decline in metabolism and endurance of skeletal muscle is commonly observed in obese patients, but the underlying mechanism is not well-understood. A research team led by Dr… read more.
A decline in metabolism and endurance of skeletal muscle is commonly observed in obese patients, but the underlying mechanism is not well-understood. A research team led by Dr… read more.
An essential part of obesity care is making sure treatments are safe for patients. Abdulrahman Alsuhibani, a doctoral student in the University of Cincinnati’s James L. Winkle College… read more.
American Society for Nutrition Statistics from the Centers for Disease Control and Prevention (CDC) show that obesity affects more than 40% of American adults, placing them at higher… read more.
A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, (iGlarLixi) met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed… read more.
Article by Bruce Sylvester. Investigative tirzepatide appears to improve glycaemic control and bodyweight in Type 2 diabetes patients, without raising the risk of hypoglycemia. Researchers reported these findings… read more.
Novo Nordisk presented data showing that an investigational 2.0 mg dose of Ozempic (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic 1.0… read more.
Article by Bruce Sylvester. Patients diagnosed with type 2 diabetes and treated with weekly semaglutide have achieved an average weight loss of almost 10kg, researchers reported on March… read more.
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda (liraglutide) is… read more.
In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass,… read more.
Article by Bruce Sylvesyter. In tandem with lifestyle management, once-weekly semaglutide therapy has enabled obese, non-diabetic patients to lose a significant amount of weight, researchers reported on Feb…. read more.
New research from the University of Sheffield has found being overweight is an additional burden on brain health and it may exacerbate Alzheimer’s disease.
Rhythm Pharmaceuticals announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for RM 493 (setmelanotide) for the treatment of pro-opiomelanocortin (POMC)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.